From Biological Data to Therapeutic Development

​

Funomics integrates genomics, microbiome science, next-generation sequencing, AI-enabled data analysis, organoid-based wet-lab validation, and advanced therapeutic development to help move scientific discoveries toward practical applications.

Our technology platform is built around three core areas:

Genomics & Microbiome Intelligence
Organoid & Wet-Lab Validation
Advanced Therapeutic Development

Together, these capabilities connect biological data with functional evidence and downstream development.

1. Genomics & Microbiome Intelligence

Turning biological data into actionable insights.

Genomics and microbiome science have been central to Funomics since 2010.

We use next-generation sequencing and bioinformatics to characterize biological systems, identify disease-associated signatures, discover biomarkers, and generate hypotheses for further experimental validation.

AI-assisted data analysis helps integrate complex genomic, microbiome, phenotypic, and experimental datasets to identify patterns and prioritize candidates for further study.

Core Capabilities

• Next-generation sequencing

• Microbiome profiling

• Microbial genomics

• Genomic data analysis

• Bioinformatics

• AI-assisted biological data analysis

• Biomarker discovery

• Candidate identification and prioritization

• Comparative genomic and microbiome analysis

Our objective is not simply to generate data. We use data to identify what should be tested next.

2. Organoid & Wet-Lab Validation

Moving from association to biological function.

Genomic and microbiome data can identify important biological associations, but experimental validation is required to determine whether those findings have functional significance.

Funomics is building a wet-lab validation platform centered on organoid models, microbiology, and functional biological assays. 

These systems allow us to test therapeutic candidates, microbial strains, metabolites, functional ingredients, and biological hypotheses in more physiologically relevant experimental models.

Core Capabilities

• Organoid-based validation

• Functional biological assays

• Candidate screening

• Host–microbe interaction studies

• Microbial culture and characterization

• Dose-response studies

• Biomarker validation

• Mechanism-oriented studies

• Comparative treatment-response studies

• Functional ingredient evaluation

By connecting sequencing data with experimental biology, Funomics helps determine whether a biological signal can be translated into a meaningful development opportunity.

3. Advanced Therapeutic Development

Translating validated science into therapeutic programs.

Funomics applies its technology platforms to the development of two primary therapeutic areas:

Small-Molecule Therapeutics

We support the advancement of promising small-molecule technologies through scientific validation, preclinical development, process development, formulation, and manufacturing readiness. 

Areas of focus include:

• Candidate evaluation

• Functional validation

• Mechanism-of-action studies

• Preclinical development

• Formulation development

• Process chemistry

• Analytical development

• CMC support

• Scale-up and technology transfer

Microbiome Therapeutics

Funomics combines microbiome sequencing, microbial genomics, functional validation, organoid models, and fermentation development to support the discovery and advancement of microbiome-based therapeutics.

Areas of focus include:

• Microbial candidate discovery

• Strain characterization

• Genomic analysis

• Functional screening

• Host–microbe interaction studies

• Organoid validation

• Fermentation development

• Formulation

• Process development

• Manufacturing readiness